Seagen

Seagen

Biotechnology, 30th Dr Se, Bothell, , 98021, Washington, 21823, United States, 1001-5000 Employees

seagen.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 42********

Who is SEAGEN

Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expand...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 621111 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SEAGEN

Seagen Org Chart and Mapping

David Epstein

Chief Executive Officer

VP-Level

Laurel Niven

Executive Assistant to SVP of Technical Development

Employees

Katrina Sebolt

Director, Medical Writing

Alyssa Schwartz

Senior Scientist, Cancer Target Discovery

Howard Baker

Associate Director, Purchasing & Services

Tamir Malik

Technical Program Manager

Anna Gall

Associate Director, Intellectual Property

Kristen Kelsey

Regional Marketing Lead

Lyma Faroz

Principal Statistical Programmer

Michelle Ubowski

Senior Clinical Scientist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Seagen

Answer: Seagen's headquarters are located at 30th Dr Se, Bothell, , 98021, Washington, 21823, United States

Answer: Seagen's phone number is 42********

Answer: Seagen's official website is https://seagen.com

Answer: Seagen's revenue is $1 Billion and Over

Answer: Seagen's SIC: 2836

Answer: Seagen's NAICS: 621111

Answer: Seagen has 1001-5000 employees

Answer: Seagen is in Biotechnology

Answer: Seagen contact info: Phone number: 42******** Website: https://seagen.com

Answer: Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing, manufacturing and commercializing targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. We work together with urgency to improve and extend the lives of people living with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability, and potency. We are working on expanding the four approved therapies for cancer while advancing new technologies with the potential to generate multiple Investigational New Drug Applications (INDs) that include next-generation ADC technologies and other novel cancer-targeting approaches.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access